Prevalence of ARV resistance mutations and impact of genotyping test in HIV patients with advance disease in São Paulo, Brazil [1]

Journal of Clinical Virology

Volumn 32, Issue 4, 2005, Pages 336-337

  Rodrigues, R ^a   Custodio R M ^a   Bueno, S M ^b   Eira, M ^c   Ferreira, J L P ^a   Jamal, L ^b   Duarte, A J S ^d   Brigido L F M ^a,e  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b Reference and Training Center for STD/AIDS   (Brazil)

^c INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e MINISTÉRIO DA SAÚDE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; BRAZIL; CLINICAL TRIAL; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LETTER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SALVAGE THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 15244339863     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.09.023     Document Type: Letter

References (14)

1. J. Casseb, L.C. Pereira Junior, and G.L. Silva Decreasing mortality and morbidity in adult AIDS patients from 1995 to 1997 in São Paulo, Brazil AIDS Patient Care STDS 13 1999 213 214
2. R.T. D'Aquila, J.M. Shapiro, and F. Brun-Vézinet Drug resistance mutation in HIV-1 Top HIV Med 10 2002 21 25
3. S. Grabar, C. Pradier, and E. Le Corfec Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor AIDS 14 2000 141 149
4. R.S. Hogg, B. Yip, and K.J. Chan Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy JAMA 286 2001 2568 2577
5. B. Ledergerber, M. Egger, and M. Opravil Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study Lancet 353 1999 863 868
6. M.R. Loutfy, and S.L. Walmsley Salvage antiretroviral therapy in HIV infection Expert Opin Pharmacother 3 2 2002 81 90
7. G.M. Lucas, R.E. Chaisson, and R.D. Moore Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions Ann Intern Med 131 1999 81 87
8. J.R.P. Marins, L.F. Jamal, and S.Y. Chen Dramatic improvement in survival among adult Brazilian AIDS patients AIDS 17 2003 1675 1682
9. J.W. Mellors, A. Munoz, and J.V. Giorgi Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection Ann Intern Med 126 1997 946 954
10. H. Mitsuya, and J. Erickson Discovery and development of antiretroviral therapeutics for HIV infection Textbook AIDS Med 1999 751 780
11. R.W. Shafer, M.J. Kozal, and M.A. Winters Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations J Infect Dis 169 1994 722 729
12. T. Shirasaka, R. Yarchoan, and M.C. O'Brien Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study Proc Natl Acad Sci USA 90 1999 562 566
13. S. Staszewski, J. Morales-Ramirez, and K.T. Tashima Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults N Engl J Méd 341 1999 1865 1873
14. F.W. Wit, R. Van Leeuwen, and G.J. Weverling Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons J Infect Dis 179 1999 790 798